open access

Vol 8, No 4 (2003)
Original papers
Published online: 2003-01-01
Submitted: 2003-06-16
Get Citation

The repeated use of high dose rate brachytherapy for locally recurrent lung cancer

Janusz Skowronek, Tomasz Piotrowski, Rodryg Ramlau, Szczepan Cofta, Krzysztof Świerkocki, Tomasz Piorunek, Witold Młynarczyk
DOI: 10.1016/S1507-1367(03)71000-1
·
Rep Pract Oncol Radiother 2003;8(4):127-137.

open access

Vol 8, No 4 (2003)
Original papers
Published online: 2003-01-01
Submitted: 2003-06-16

Abstract

Purpose

To assess the effect of repeated palliative treatment with high dose rate brachytherapy in patients with advanced lung cancer.

Material and Methods

Fifty-six patients, 25.3% of a total of 221 patients treated for lung cancer with HDR brachytherapy were treated twice, using High Dose Rate Brachytherapy. All patients were qualified for repeated brachytherapy due to the recurrence of intrabronchial tumour and acceptable remissions after the first treatment. The survival times were compared with selected clinical data. Correlations between survival times and subjective breathing difficulties were analyzed separately.

Results

The median survival time in the whole group of patients was 8.9 months. The period of obtaining a positive clinical response was correlated with a longer survival time (log-rank test, p=0.0009, F Cox test, p=0.007). In the multivariate analysis other statistically important prognostic factors were also included: the clinical stage of the primary tumour (F Cox test, p=0.04), and the interval between the first and second treatment (F Cox, p=0.004). None of the analyzed factors (dyspnoea, cough, haemoptysis and pain) had any influence on survival.

Conclusion

Repeated HDR brachytherapy in advanced lung cancer was an efficient method that in many patients led to regression of symptoms and improvement in life quality.

Abstract

Purpose

To assess the effect of repeated palliative treatment with high dose rate brachytherapy in patients with advanced lung cancer.

Material and Methods

Fifty-six patients, 25.3% of a total of 221 patients treated for lung cancer with HDR brachytherapy were treated twice, using High Dose Rate Brachytherapy. All patients were qualified for repeated brachytherapy due to the recurrence of intrabronchial tumour and acceptable remissions after the first treatment. The survival times were compared with selected clinical data. Correlations between survival times and subjective breathing difficulties were analyzed separately.

Results

The median survival time in the whole group of patients was 8.9 months. The period of obtaining a positive clinical response was correlated with a longer survival time (log-rank test, p=0.0009, F Cox test, p=0.007). In the multivariate analysis other statistically important prognostic factors were also included: the clinical stage of the primary tumour (F Cox test, p=0.04), and the interval between the first and second treatment (F Cox, p=0.004). None of the analyzed factors (dyspnoea, cough, haemoptysis and pain) had any influence on survival.

Conclusion

Repeated HDR brachytherapy in advanced lung cancer was an efficient method that in many patients led to regression of symptoms and improvement in life quality.

Get Citation

Keywords

Lung Cancer; HDR Brachytherapy; Reirradiation; Recurrence

About this article
Title

The repeated use of high dose rate brachytherapy for locally recurrent lung cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 8, No 4 (2003)

Pages

127-137

Published online

2003-01-01

DOI

10.1016/S1507-1367(03)71000-1

Bibliographic record

Rep Pract Oncol Radiother 2003;8(4):127-137.

Keywords

Lung Cancer
HDR Brachytherapy
Reirradiation
Recurrence

Authors

Janusz Skowronek
Tomasz Piotrowski
Rodryg Ramlau
Szczepan Cofta
Krzysztof Świerkocki
Tomasz Piorunek
Witold Młynarczyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl